Business Wire

Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research

Share

Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.

Ultivue develops unique solutions for use in mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples. This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.

Ultivue recognizes the need for dedicated and custom AI models to analyze the complexity of mIF data at scale and to provide improved turn-around times and consistent readouts across large cohorts “We are looking forward to accelerating data generation for biopharma customers from mIF kits by partnering with Keen Eye. We can jointly support more scalable workflows which will allow us to meet increasing demand in clinical trials.” said Florian Leiss, Ph.D. Vice President Digital Health Strategies at Ultivue.

Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis. Its proprietary models dedicated for spatial exploration of tumor microenvironment give access to reliable tissue segmentation, biomarker quantification, cell population profiling, and morphological discovery.

Thanks to Ultivue’s pre-optimized assays, the high accuracy achieved for every biomarker will drastically reduce errors during quantification steps as phenotypes combine several biomarkers. As Dr. Sylvain Berlemont, Keen Eye’s founder and CEO says, “We are thrilled to expand our application portfolio combined with best-in-class Ultivue mIF assays to biopharma companies and CROs. This partnership will undeniably support our customers to fully extend reproducibility and scalability throughout their clinical research.”.

About Keen Eye

Keen Eye is a health technology company based in Paris, aiming to bring AI into every research laboratory, CRO and pharmaceutical company, for the benefit of biologists, pathologists, and patients. Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms. Keen Eye strives to support the development of new therapies with better, faster, and accurate analytics. Learn more at keeneye.ai.

About Ultivue

Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Keen Eye
Sylvain Berlemont, Ph.D
CEO and Founder
sylvain.berlemont@keeneye.ai

Ultivue
Florian Leiss Ph.D
Vice President Digital Health Strategies
Florian.leiss@ultivue.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dental Monitoring Launches the Virtual Practice Platform for a Comprehensive, Life-Long Patient Experience18.5.2022 22:10:00 CEST | Press release

Dental Monitoring, the industry-leading company that pioneered the field of intelligent orthodontics, launches the Virtual Practice Platform for a comprehensive, life-long patient experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518006088/en/ More information: (Photo: Business Wire) This groundbreaking Virtual Practice Platform is designed for doctors and patients to partner along the entire treatment journey through a suite of intelligent workflows and tools. By using the platform, doctors will be able to identify, engage, qualify, and convert leads, optimize treatment and monitor patients, as well as benefit from opportunities for new revenue streams. Dental Monitoring is launching the Virtual Practice Platform as the increasing need for remote and intelligent care in the dental industry meets growing patient expectations. Through the platform, the SaaS company aims to spearhead widespread transformation for p

Align Announces Additional Leadership for UK and EMEA to Support Continued Growth18.5.2022 17:11:00 CEST | Press release

Align, the premier global provider of technology infrastructure solutions celebrates significant growth throughout the UK and EMEA markets with management changes to support increasing demand. The appointment of Giulia Marcolina as Managing Director and Mike Konold as AV Solutions Director of Align’s UK-based headquarters, will enable the team to deliver innovative collaborative technology and state-of-the-art AV solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005833/en/ Giulia Marcolina, a 15 year veteran with Align, is named Managing Director of Align's UK-based headquarters. (Photo: Business Wire) Giulia brings over 25 years of IT experience, previously serving as Align’s Programme Manager, delivering corporate office relocation and consolidation projects for clients such as Blackrock, Total Gas and Power, and UBS. In her new role, she will lead Align’s team of project managers in building upon Align’s lon

RMS Advances Climate Risk Modeling and Moves More Models to High Definition18.5.2022 16:30:00 CEST | Press release

RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, today announces it will be releasing four new High Definition™ (HD) models, including Europe Windstorm, North America Winterstorm (WT), North America Severe Convective Storm (SCS), and Terrorism. RMS HD Models represent the next generation of risk modeling, delivering deeper analysis and granularity from Moody’s. The HD probabilistic models incorporate a high-fidelity, simulation-based framework for modeling event frequency and severity, to provide a major step forward in the quality of catastrophe risk quantification. The framework allows for event footprints to be represented more realistically across larger event sets. The new RMS Europe Windstorm HD Model further enhances the current model and will cover 17 countries, adding Finland and Lichtenstein. The HD model includes a climate variability view and has expanded storm surge analytics to include the U.K., Ireland, France, and Belgium. Storm c

Suketu Upadhyay Elected to Vertex Board of Directors18.5.2022 16:30:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyayhas been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. “We are delighted to have Suky join the Vertex Board. His extensive financial and strategic experience in health care, paired with his leadership and expertise across biopharma and medtech, make him a valuable addition to our board of directors,” said Reshma Kewalramani, M.D., Vertex’s Chief Executive Officer and President. “It’s an honor to join Vertex, a company focused on serial innovation with an

Armory Makes Continuous Deployment Achievable and Effortless, at any Scale, for all Developers18.5.2022 16:17:00 CEST | Press release

Armory, the Continuous Deployment company empowering development teams to easily, reliably, safely, and continuously deploy software at any scale, today announced public early access to their new Continuous Deployment-as-a-Service product. Armory Continuous Deployment-as-a-Service delivers declarative deployments, across multiple environments, that support advanced strategies, so developers can focus on building great code rather than deploying it. “We believe deploying software continuously, at any scale, should be achievable and effortless for all developers of the world, not just the likes of Google and Netflix,” said Jim Douglas, President and CEO, Armory. “It’s our vision and mission to unlock innovation through software to make software continuous, scalable, secure, and safe, so developers can improve and protect their customers’ experience with confidence and ease.” To effectively compete in a software-defined world, development teams must ensure a stellar customer experience. S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom